Neuren Pharmaceuticals Limited
NURPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.56B
Close$
$2.03
85.8% downside
Current Fair Value
85.8% downsideOvervalued by 85.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.56 Billion |
|---|---|
| Enterprise Value | - |
| Annual dividend | $0.10 |
| Dividend yield | 0.74% |
| Earnings per Share | $0.24 |
| Beta | 1.59 |
| Outstanding Shares | 126,773,976 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 127.61 |
|---|---|
| PEG | -188.31 |
| Price to Sales | 7.14 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$22.25 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
$0.20
Consensus analyst estimateRevenue Estimate
$55.41 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Neuren Pharmaceuticals Limited
9 employees
CEO: Jonathan Charles Pilcher
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patie...